Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program
Spruce Biosciences, a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, has announced the launch of CAHstudy.com a new website and patient resource to enable adults with Congenital Adrenal Hyperplasia (CAH) to register their interest in the CAHmelia clinical program, which is expected to commence in the second half of 2020.
The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo -controlled, late stage clinical studies in adults with Classic CAH. In September 2019, Spruce Biosciences announced positive results from a Phase 2, multicenter, 12-week study of tildacerfont in adult patients with Classic CAH.
“Our previous studies have demonstrated promising safety and efficacy results from the use of tildacerfont in adults with Classic CAH,” said Richard King, Chief Executive Officer. “We are excited to move forward with the CAHmelia clinical program and encourage CAH patients and their families to visit CAHstudy.com to register their interest in the study and begin the screening process.
Interested clinical study participants across the United States are encouraged to visit CAHstudy.com to complete a short questionnaire and determine their eligibility for the CAHmelia clinical program.
The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo -controlled, late stage clinical studies in adults with Classic CAH. In September 2019, Spruce Biosciences announced positive results from a Phase 2, multicenter, 12-week study of tildacerfont in adult patients with Classic CAH.
“Our previous studies have demonstrated promising safety and efficacy results from the use of tildacerfont in adults with Classic CAH,” said Richard King, Chief Executive Officer. “We are excited to move forward with the CAHmelia clinical program and encourage CAH patients and their families to visit CAHstudy.com to register their interest in the study and begin the screening process.
Interested clinical study participants across the United States are encouraged to visit CAHstudy.com to complete a short questionnaire and determine their eligibility for the CAHmelia clinical program.
NADF is not endorsing the product, merely informing our members with CAH about a new clinical trial.
